Outcomes in patients with recurrent/progressive glioblastoma treated with bevacizumab funded by a regional cancer drug fund

Clin Oncol (R Coll Radiol). 2014 Apr;26(4):238-9. doi: 10.1016/j.clon.2014.01.002. Epub 2014 Jan 22.

Authors

S Dixit¹, P Hatfield², S Clenton³, C Loughrey², M Hingorani¹

Affiliations

¹ Hull & East Yorkshire Hospitals NHS Trust, Hull, UK.
² Leeds Teaching Hospitals NHS Trust, St. James's Institute of Oncology, Leeds, UK.
³ Sheffield Teaching Hospitals NHS Foundation Trust, Weston Park Hospital, Sheffield, UK.

PMID: 24461951
DOI: 10.1016/j.clon.2014.01.002

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / economics*
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents / economics*
Antineoplastic Agents / therapeutic use*
Bevacizumab
Disease Progression
Drug Costs
Glioblastoma / drug therapy*
Glioblastoma / economics
Humans
Neoplasm Recurrence, Local / drug therapy
Neoplasm Recurrence, Local / economics
State Medicine / economics
Treatment Outcome
United Kingdom

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Bevacizumab